The Role of PCSK9 in In-stent Restenosis After PCI and Related Mechanism
10.3870/j.issn.1672-0741.23.01.007
- VernacularTitle:PCSK9在PCI术后支架内再狭窄中的作用及机制
- Author:
Ziyu YI
1
;
Guofu ZHU
Author Information
1. 昆明医科大学研究生院,昆明 650500
- Keywords:
PCSK9;
percutaneous coronary intervention;
in-stent restenosis;
acting mechanism
- From:
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
2024;53(3):403-408
- CountryChina
- Language:Chinese
-
Abstract:
Proprotein convertase subtilisin/kexin type 9(PCSK9)is a protein that is synthesized and secreted from hepato-cytes.It can reduce low-density lipoprotein(LDL)uptake by promoting degradation of LDL receptor(LDLR)on the surface of hepatocyte.Since application of PCSK9 inhibitors become more common,researchers have found that PCSK9 can regulate ather-osclerosis development,platelet activation and thrombosis,inflammation,and glycolipid metabolism.PCSK9 is also the main in-ducements of in-stent restenosis(ISR)after percutaneous coronary intervention(PCI).Therefore,this article reviews the research progress of mechanism of PCSK9 in ISR after PCI,and makes a preliminary prospect on the application of PCSK9 as a therapeu-tic target in coronary atherosclerotic heart disease.
